Drug intelligence / Profile preview

quinfamide

Development stage: Phase 4
Lead developer: Janssen Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Quinfamide is a small molecule anti-parasitic drug belonging to the quinoline family, specifically a dichloroacetamide derivative. It acts as a luminal amebicide and antiprotozoal agent, primarily used for the treatment of intestinal amoebiasis and helminthiasis. Its mechanism of action involves interfering with protozoan metabolism, leading to immobilization and death of parasites such as *Entamoeba histolytica*. The drug is administered orally and has been shown to be effective in both acute and chronic intestinal infections[1][3][6][8].

Brand names: AmecidAmefinAmenideAmenoxAmenox InfantilAmoebrizAmofarmaBensolminBisidimFarmiverOxalProtosinQuinfateg PlusQuocelSerphamidaVermox PlusZentel Dual
Other names: quinfamideQuinfamidumQuinfamidQuinfamida

Beyond the preview

Go deeper on quinfamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on quinfamide.

Explore the full profile